T-DXd: New Standard for HER2-Low Breast Cancer
Unknown authors
Abstract
Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer. T-DXd should be considered a new standard of care for these patients, who otherwise have limited options.
Topics & Concepts
TrastuzumabMedicineBreast cancerOncologyConjugateInternal medicineAntibodyMetastatic breast cancerCancerCancer researchImmunologyMathematical analysisMathematicsHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyBreast Cancer Treatment Studies